Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | USP7 | Q93009 | 6/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | MAP2 | P11137 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675800 | 0.86 | USP7 (0.36) | FYNUSP7 | |
| SCHEMBL14675799 | 0.86 | USP7 (0.36) | FYNUSP7 | |
| SCHEMBL21141641 | 0.81 | MEN1 (0.35) | USP7ABL1 | |
| SCHEMBL16194553 | 0.77 | FFAR4 (0.45) | FYNUSP7MKNK1MKNK2CASP1 | |
| SCHEMBL11256987 | 0.77 | USP7 (0.45) | USP7ABL1CLK1DYRK1ADYRK2 | |
| SCHEMBL14675836 | 0.76 | FTO (0.48) | — | |
| SCHEMBL15730886 | 0.74 | ABL1 (0.44) | PARP1MKNK1MKNK2ABL1CASP1 | |
| SCHEMBL13562437 | 0.73 | MKNK1 (0.60) | FYNMKNK1MKNK2MAP4K4ABL1 | |
| SCHEMBL16193947 | 0.73 | SQOR (0.41) | FYNUSP7MKNK1MKNK2CTSA | |
| SCHEMBL16193957 | 0.73 | USP7 (0.36) | FYNUSP7CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | claimed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | claimed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | claimed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | claimed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3782616-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | The Regents of The University of California (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3189026-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| EP-3189026-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | The Regents of The University of California (US) | 2017-07-12 | — | — | EP | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| WO-2017031276-A1 | METHODS OF PROVIDING NEUROPROTECTIVE THERAPY RELATED TO ADMINISTERING AN ESTROGEN RECEPTOR BETA LIGAND | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2016036721-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008002-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | FYN 2896/4885PARP1 4194/4885USP7 2611/4885 |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | FYN 2896/4885PARP1 4194/4885USP7 2611/4885 |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | FYN 3194/4885PARP1 4789/4885USP7 1983/4885 |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | FYN 2896/4885PARP1 4194/4885USP7 2611/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | FYN 2896/4885PARP1 4194/4885USP7 2611/4885 |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | FYN 3194/4885PARP1 4789/4885USP7 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.